FDA Wants Improved Products To Prevent Kidney Transplant Rejection
This article was originally published in The Pink Sheet Daily
Executive Summary
Acute antibody-mediated rejection can be treated successfully 90 percent of the time, but designing a trial for another therapy might prove difficult..
You may also be interested in...
Luveniq Advisory Committee: Renal Side Effects May Be Key Issue With Immunosuppressant
Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: